October 15, 2018 (Vol. 38, No. 18)


These human induced pluripotent stem cell (hiPSC)-derived atrial cardiomyocytes can be used to develop therapeutics for cardiovascular diseases. Generated from the same donor as highly validated hiPSC-derived ventricular cardiomyocytes, this physiologically relevant hiPSC-derived cell line is quick and easy to use, ready in just seven days from thaw, for electrophysiology, cardiac contractility study, screening, and the investigation of cardiomyopathies. These hiPSC-derived atrial cardiomyocytes express typical targets, ion channels, and currents (Kv1.5, Ikir3.x, Ikur, IKACh, MLC2a, and ANP) essential for the screening of cross-target effects, the development of atrial specific target drugs, and the investigation of atrial fibrillation and inherited cardiac conditions.

Previous articleMouse Pups Have Two (Biological) Mommies
Next articleFat Tissue Found to Be a Surprising Source of Diabetes